Back to comparisons

Comparison

NMN vs Apigenin

FieldNMNApigenin
Categoryneuroprotectiveneuroprotective
Dose range250–1000mg50–100mg
Half-life
Onset
EvidenceEVIDENCEBEVIDENCEB
Safety●●●●●●●●●●
Legal (US)USOTCUSOTC
PubMed refs600400

The comparison in plain English

Auto-generated from data

NMN and Apigenin are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. Apigenin Flavonoid found in chamomile, parsley, and celery.

Bottom line

NMN (evidence B, safety 5/5) matches the evidence base of Apigenin (evidence B, safety 5/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.

Choose NMN if

NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.

Choose Apigenin if

Apigenin is the better fit when your goal aligns with its mechanism (Partial agonist at GABA-A receptors at the benzodiazepine binding site, producing mild anxiolytic and sleep-promoting effects without the dependence profile of pharmaceutical benzodiazepines) and the dose range (50–100mg) suits your protocol. Half-life is —h.

Build a stack with bothOpen builder →
Check interactionsOpen checker →